BBT-176 gets approval for Phase 1 and 2 trials by FDABridge Biotherapeutics said Monday that it has received approval from the U.S. Food and Drug Administration to start Phase 1 and 2 clinical trials for BBT-176.
BBT-176, a third-generation therapy for non-small cell lung cancer, will be tested with a small number of patients in Korea through a dose escalation study. The treatment from Bridge Biotherapeutics is separate from AstraZeneca’s Tagrisso.
BBT-176 will tested again in the United States and Korea. The studies will be used to observe safety, tolerability and anti-tumor efficacy of BBT-176 among patient groups.
The candidate substance, which was first discovered by the Korea Research Institute of Chemical Technology, was licensed to Bridge Biotherapeutics in late 2018.
By Ko Jun-tae
More in Industry
No dial tone for 2G services on LG U+ starting in June
Ironing out an air corridor took decades
Kia reinvents itself, promising 'movement that inspires'
Hanwha Energy teams up with France's Total in U.S.
Scatter Lab investigated, but not for odd messages